Bio-Rad Laboratories (BIO) to Release Quarterly Earnings on Thursday

Bio-Rad Laboratories (NYSE:BIO) will release its earnings data after the market closes on Thursday, August 1st. Analysts expect Bio-Rad Laboratories to post earnings of $2.12 per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Tuesday, May 7th. The medical research company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.04 by $0.25. Bio-Rad Laboratories had a positive return on equity of 3.59% and a negative net margin of 12.37%. The firm had revenue of $610.82 million for the quarter, compared to analysts’ expectations of $619.09 million. During the same period last year, the firm earned $3.34 EPS. The firm’s revenue was down 9.8% compared to the same quarter last year. On average, analysts expect Bio-Rad Laboratories to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Bio-Rad Laboratories Trading Up 1.9 %

Shares of BIO stock opened at $325.61 on Tuesday. Bio-Rad Laboratories has a 1 year low of $261.59 and a 1 year high of $419.00. The stock has a fifty day moving average of $289.27 and a two-hundred day moving average of $306.99. The company has a current ratio of 6.57, a quick ratio of 4.89 and a debt-to-equity ratio of 0.13.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Monday, July 22nd. Jefferies Financial Group reaffirmed a “hold” rating and issued a $315.00 price target (down from $440.00) on shares of Bio-Rad Laboratories in a research note on Monday, June 3rd. UBS Group decreased their price objective on shares of Bio-Rad Laboratories from $420.00 to $385.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Finally, Citigroup cut Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $400.00 to $365.00 in a report on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Bio-Rad Laboratories has an average rating of “Moderate Buy” and a consensus price target of $436.67.

Insider Transactions at Bio-Rad Laboratories

In other news, EVP Michael Crowley sold 369 shares of the stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $281.91, for a total value of $104,024.79. Following the completion of the sale, the executive vice president now owns 6,573 shares in the company, valued at $1,852,994.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.